verified SJR 0,532 · Q3 • database Scopus / SJR & Web of Science indexed

United States · Lippincott Williams and Wilk...

workspace_premium Q3 — Pharmacology lock Subscription Unclaimed

Anti-Cancer Drugs

Anti-Cancer Drugs is a journal indexed in SJR in Pharmacology and Oncology with an H index of 105. It has a price of 2040 €. It has an SJR impact factor of 0,532 and it has a best quartile of Q3. It is published in English. It has an SJR impact factor of 0,532.

Anti-Cancer Drugs focuses its scope in these topics and keywords: carcinoma, antitumor, modulator, prognostic, cancerceragenin, effects, glasgow, induces, patient, management, ...

ISSN: 0959-4973

Editorial: Lippincott Williams and Wilkins

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guidelines NPD

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

0,532 Q3

H-index 105

Tasa de Aceptación pie_chart

25% Selectiva

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

2.040 € Subscription

Ruta Non-OA 0 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

0,532

H-index

105

Docs (year)

135

Docs 3y

525

Total refs

4055

Cites 3y

1094

Citable 3y

523

Cites/Doc 2y

2.13

Ref/Doc

30.04

Immediate OA

2040 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Biochanin A inhibits endothelial cell functions and proangiogenic pathways

Zerumbone inhibits growth of hormone refractory prostate cancer cells by inhibiting JAK2/STAT3 pathway and increases paclitaxel sensitivity

EDITORIAL BOARD

Editorial

Dysregulation of protein kinase C activity in chemoresistant metastatic breast cancer cells

Dextran sulfate inhibits injured abdominal wall-specific tumor implantation in mice

Cytotoxic effect in vivo and in vitro of CHS 828 on human myeloma cell lines

Congestive heart failure in a 77-year-old woman receiving adjuvant treatment with imatinib for a large gastric gastrointestinal stromal tumour

Complications mimicking lupus flare-up in a uremic patient undergoing pegylated liposomal doxorubicin therapy for cervical cancer

Complete remission of multiple lung metastases after ablation of hepatocellular carcinoma by transarterial infusion with the p53 gene

Combination with liposome-entrapped, ends-modified raf antisense oligonucleotide (LErafAON) improves the anti-tumor efficacies of cisplatin, epirubicin, mitoxantrone, docetaxel and gemcitabine

Caffeic acid phenethyl ester induces growth arrest and apoptosis of colon cancer cells via the ??-catenin/T-cell factor signaling

SHOW MORE ARTICLES

Biochanin A reduces pancreatic cancer survival and progression

19F-magnetic resonance spectroscopy in patients with liver metastases of colorectal cancer treated with 5-fluorouracil

Assessment of cyclooxygense-2 expression with 99mTc-labeled celebrex

Approach to a multiparametric sensor-chip-based tumor chemosensitivity assay

Apoptosis-inducing oxovanadium(IV) complexes of 1,10-phenanthroline against human ovarian cancer

Antitumor activity of XR5944, a novel and potent topoisomerase poison

Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models

Antimelanoma activity of 1,3,4-thiadiazolium mesoionics: a structure-activity relationship study

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities

A systematic review and pooled analysis of retrospective series of eribulin in metastatic breast cancer

A small randomized phase III single-center trial on postoperative UFT administration in patients with completely resected non-small cell lung cancer

A phase II study of epirubicin, vinorelbine and cisplatin in advanced breast cancer

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.